ERTUGLIFLOZIN AND SITAGLIPTIN (STEGLUJAN) Nursing Considerations

What is the generic name?

ERTUGLIFLOZIN AND SITAGLIPTIN

What is the Trade Name for ERTUGLIFLOZIN AND SITAGLIPTIN?

STEGLUJAN

What are the Indications for ERTUGLIFLOZIN AND SITAGLIPTIN?

• 1 INDICATIONS AND USAGE STEGLUJAN ¬Æ is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Not recommended in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients [see Warnings and Precautions (5.2) ]. Has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using STEGLUJAN [see Warnings and Precautions (5.1) ] . STEGLUJAN is a combination of ertugliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, and sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: Not for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. It may increase the risk of diabetic ketoacidosis in these patients. ( 1 ) Has not been studied in patients with a history of pancreatitis. ( 1 , 5.1 )

References: https://open.fda.gov/